Published in Biotech Law Weekly, November 18th, 2005
Study 1: The effect of chemotherapy-induced amenorrhea during adjuvant therapy was studied recently by scientists in Canada.
Scientists sought "To investigate the therapeutic impact of chemotherapy-induced amenorrhea in premenopausal patients with breast cancer" by conducting "a retrospective cohort study of a National Cancer Institute of Canada Clinical Trials Group phase III trial involving premenopausal patients randomized to receive cyclophosphamide, methotrexate, and fluorouracil (CMF), versus intensive cyclophosphamide, epirubicin, and fluorouracil (CEF)."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.